REPLIMUNE GROUP INC

Replimune Group (REPL) shares jumped 2.63% to $11.61, lifting above its 200‑day SMA. Explore the latest price action, market cap, and peer‑benchmarks for this oncology biotech.

Replimune (REPL) rises 2.63% as new clinical data sparks optimism. Learn how biotech trends and Q3 2026 updates may shape its $1.1bn valuation.

Replimune (REPL) shares up 3.35% today, trading at $11.42 with a $1 billion cap and 52‑week high at $16.33—investors see oncolytic therapy potential.

Replimune’s recent 1.75% dip highlights the high‑risk, high‑reward nature of its oncolytic immunotherapy focus, with a modest price rise amid heavy R&D spending and market volatility.